Recent Quotes (30 days)

You have no recent quotes
chg | %

Antibe Therapeutics Inc  

(Public, CVE:ATE)   Watch this stock  
Find more results for ATE
+0.055 (36.67%)
Mar 26 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.17 - 0.22
52 week 0.04 - 0.84
Open 0.17
Vol / Avg. 1.85M/527,124.00
Mkt cap 7.59M
P/E     -
Div/yield     -
EPS -0.14
Shares 37.01M
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin -16961.97% -42540.64%
Operating margin -16961.97% -42299.84%
EBITD margin - -42299.84%
Return on average assets -175.33% -105.32%
Return on average equity -219.15% -231.86%
Employees 3 -
CDP Score - -


15 Prince Arthur Ave

Website links


Antibe Therapeutics Inc. develops and out-licenses protected new pharmaceuticals. The Company�s drug design methodologies involve chemically linking an existing drug (base drug) to an Antibe-patented, hydrogen sulfide-releasing molecule; hydrogen sulfide (H2S) is the key gaseous mediators and has anti-inflammatory, anti-nociceptive (pain-killing) and vasodilatory properties. The Company�s lead compound, ATB-346, combines a gaseous mediator (H2S) with naproxen, a widely used NSAID, to create a novel therapeutic compound. The Company�s drug development pipeline include ATB-346, ATB-344 and other candidates.

Officers and directors

Walter M. Macnee Independent Chairman of the Board
Age: 59
Daniel Legault J.D. President, Chief Executive Officer, Secretary, Director
Age: 56
John L. Wallace Ph.D. Founder, Chief Scientific Officer, Director
Age: 57
Michael Bumby Chief Financial Officer
Age: 50
Jeremy Grushcow Executive Vice President - Strategic Development
David Vaughan Chief Development Officer
Age: 63
Roderick J. Flower Ph.D. Independent Director
Age: 69
Jonathan Ross Goodman Independent Director
Age: 46
Samira Sakhia CPA Independent Director